Drug Trial Radar · NCT05881382
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
Last checked: Nov 20, 2026Latest source record: Jun 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
4,100
Planned (sponsor's estimate)
Start
Sep 2023
Primary completion
Sep 2025
Study completion Sep 2025
Sponsor
- Lead sponsor
- Recardio, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this phase 3, randomized, double-blind, placebo-controlled clinical trial is to explore the safety and efficacy of dutogliptin administered subcutaneously (SC) in co-administration with filgrastim in adult patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The primary objective is to evaluate the efficacy of dutogliptin compared with placebo in STEMI patients within 180 days of randomization measured by the time of first occurrence of a composite endpoint of cardiovascular (CV) death and worsening heart failure (HF) within 180 days. Participants will receive dutogliptin twice daily subcutaneously (SC) for 14 days and filgrastim (SC) daily for 5 days or placebo.
Conditions
- ST Elevation Myocardial Infarction
Interventions
Dutogliptin + FilgrastimDrug
dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.
PlaceboDrug
Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time of first occurence of the following composite endpoint of cardiovascular (CV) death and worsening of heart failure (HF)Time frame: within 180 days of randomization
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.